Immatics Reports Strong Clinical Data Across Three Cancer Therapies, Including Phase 3 Anzu-cel Program
IMTX has more than doubled off its 52-week low of $5.05.
Summary
Immatics N.V. reported updated positive Phase 1 clinical data for its IMA203CD8, IMA401, and anzu-cel (IMA203) cancer therapies, highlighting strong efficacy and manageable tolerability across various solid tumors, with anzu-cel advancing towards a Phase 3 BLA submission.
Key Events · Product Development and Regulatory · IMTX
-
Anzu-cel (IMA203) Shows Strong Efficacy in Advanced Melanoma
The PRAME TCR T-cell therapy, anzu-cel, demonstrated a 56% confirmed objective response rate (cORR), 14.6 months median duration of response (mDOR), 6.1 months median progression-free survival (mPFS), and 16.2 months median overall survival (mOS) in heavily pretreated advanced melanoma patients. 42% of patients achieved deep responses (≥50% tumor reduction) with a mPFS of 15.9 months. Tolerability remained predictable and manageable.
-
Anzu-cel Advances Towards Commercialization
The positive data for anzu-cel supports its continued development, with the Phase 3 SUPRAME clinical trial ongoing and a Biologics License Application (BLA) submission expected in the first half of 2027. A Phase 2 cohort in metastatic uveal melanoma is also ongoing to support potential label expansion.
-
IMA203CD8 Shows Broad Activity in Gynecologic Cancers and Synovial Sarcoma
The PRAME TCR T-cell therapy, IMA203CD8, achieved a 63% objective response rate (ORR) and 50% cORR in gynecologic cancers (including 4 complete responses), with 89% of confirmed responses ongoing. In synovial sarcoma, it showed a 67% ORR and 64% cORR, with responses ongoing for up to 3 years. The therapy demonstrated manageable tolerability, and the recommended Phase 2 dose (RP2D) is expected in 2026.
-
IMA401 Bispecific Demonstrates Activity in Solid Tumors
The MAGEA4/8 TCR bispecific, IMA401, showed a 29% cORR in head and neck cancer (with 60-100% tumor reduction in responders) and 33% cORR in melanoma. It also provided a promising clinical signal in squamous cell non-small cell lung cancer (sqNSCLC). Tolerability was manageable as monotherapy or in combination with pembrolizumab.
Analysis · IMTX · Life Sciences
Immatics N.V. announced updated positive Phase 1 clinical data for three of its key oncology programs: IMA203CD8, IMA401, and anzu-cel (IMA203). The data demonstrates encouraging efficacy and manageable tolerability across multiple difficult-to-treat solid tumors. The continued progress of anzu-cel, with robust response rates and durability in advanced melanoma and an ongoing Phase 3 trial targeting a BLA submission in 1H 2027, is a significant step towards potential commercialization. Additionally, the promising early-stage data for IMA203CD8 in gynecologic cancers and synovial sarcoma, and IMA401 in head & neck cancer and melanoma, supports the broad potential of the company's PRAME-targeting franchise and bispecific platform. The initiation of the IMA401/IMA402 combination trial further expands the company's strategic development.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMTX was trading at $11.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $5.05 to $12.41. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.